Skip to content
DataLookout
Menu

NCT07310264

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 5 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Sep 28, 2026 to Nov 10, 2026
    • Enrollment target: estimated 84 to confirmed 80
    • Secondary endpoints: details revised at 4 of 14 entries
    • Site details revised
  2. Notable Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 15 to 14
    • Study description expanded, about 4 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants with treatment-related adverse events (AEs)
Timeframe: Part A: Up to 8 days; Part B: Up to 15 days; Part C: Up to 35 days;

Secondary (14)

Plasma pharmacokinetic (PK) parameter: Cmax
Plasma PK parameter: Tmax
Plasma PK parameter: AUClast
Plasma PK parameters: AUCinf
Plasma PK parameter: t1/2
Show 9 moreShow less
Plasma PK parameter: Apparent CL/F
Plasma PK parameter: Apparent Vd/F
Food effect on plasma PK: Cmax
Food effect on plasma PK: Tmax
Food effect on plasma PK: AUC
Urine PK parameter: CLr
Urine PK parameter: Cumulative amount excreted (urine)
Urine PK parameter: %Cumulative amount excreted
Feces PK parameter: Observed concentration

Arms and interventions

Part A SAD ActiveExperimental

Single Ascending Doses of VT-5006

Part A SAD PlaceboPlacebo comparator

Matched Placebo

Part B MAD ActiveExperimental

Multiple ascending doses of VT-5006

Part B MAD PlaceboPlacebo comparator

Matched Placebo

Part C Active Low DoseExperimental

Low dose VT-5006

Part C Active High DoseExperimental

High dose VT-5006

Part C PlaceboPlacebo comparator

Matched placebo

Drugs: VT-5006, Placebo

Sites

1 site in 1 country

  • Center for Human Drug ResearchLeiden, Netherlands